Type 2 Diabetes in Obesity: A Systems Biology Study on Serum and Adipose Tissue Proteomic Profiles
Por:
Arderiu G., Mendieta G., Gallinat A., Lambert C., Díez-Caballero A., Ballesta C., Badimon L.
Publicada:
1 ene 2023
Ahead of Print:
3 ene 2023
Resumen:
Obesity is associated with metabolic disorders such as insulin resistance and type 2 diabetes mellitus (T2DM), further increasing an already heightened cardiovascular risk. Here, amongst obese class III bariatric surgery patients, we have investigated the effect of T2DM in serum and in two, same patient, adipose tissue (AT) depots through proteomic profile expression analyses. Serum and AT samples from subcutaneous (SAT) and visceral (VAT) fat were collected during bariatric surgery. Bead-based targeted multiplex assay systems were used to simultaneously detect and quantify multiple targets in serum samples (targeted proteomics) and analyze changes in adipokine serum composition. AT samples were assessed through an untargeted proteomics approach. Through a systems biology analysis of the proteomic data, information on the affected biological pathways was acquired. In obese class III individuals, the presence of T2DM induced a significantly higher systemic release of ghrelin, GLP-1, glucagon, MMP3, BAFF, chitinase 3-like 1, TNF-R1 and TNF-R2, and a lower systemic release of IL-8. SAT and VAT proteomes belonging to the same patient showed significant differences in local protein content. While the proteins upregulated in VAT were indicative of metabolic dysregulation, SAT protein upregulation suggested adequate endocrine regulation. The presence of T2DM significantly affected VAT protein composition through the upregulation of dysregulating metabolic pathways, but SAT protein composition was not significantly modified. Our results show that T2DM induces metabolic dysregulation in obese individuals with changes in systemic marker levels and impairment of proteostasis in VAT but not in SAT.
Filiaciones:
Arderiu G.:
Inst Invest Biomed St Pau IIB St Pau, Cardiovasc Program, Barcelona 08041, Spain
Ctr Invest Biomed Red Enfermedades Cardiovasc Cib, Barcelona 28029, Spain
Mendieta G.:
Ctr Nacl Invest Cardiovasc CNIC, Madrid 28029, Spain
Gallinat A.:
Inst Invest Biomed St Pau IIB St Pau, Cardiovasc Program, Barcelona 08041, Spain
Lambert C.:
Inst Invest Biomed St Pau IIB St Pau, Cardiovasc Program, Barcelona 08041, Spain
IPSA Inst Invest Sanitaria Principado Asturias, Oviedo 33011, Spain
Díez-Caballero A.:
Ctr Med Teknon, Grp Quiron Salut, Barcelona 08022, Spain
Ballesta C.:
Ctr Med Teknon, Grp Quiron Salut, Barcelona 08022, Spain
Badimon L.:
Inst Invest Biomed St Pau IIB St Pau, Cardiovasc Program, Barcelona 08041, Spain
Ctr Invest Biomed Red Enfermedades Cardiovasc Cib, Barcelona 28029, Spain
Green Published, gold, All Open Access, Gold, Green
|